CSTL Relative Valuation
CSTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CSTL is overvalued; if below, it's undervalued.
Historical Valuation
Castle Biosciences Inc (CSTL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -20.54. The fair price of Castle Biosciences Inc (CSTL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：40.19
Fair
-27.51
PE
1Y
3Y
5Y
Trailing
Forward
52.81
EV/EBITDA
Castle Biosciences Inc. (CSTL) has a current EV/EBITDA of 52.81. The 5-year average EV/EBITDA is -16.08. The thresholds are as follows: Strongly Undervalued below -50.92, Undervalued between -50.92 and -33.50, Fairly Valued between 1.34 and -33.50, Overvalued between 1.34 and 18.75, and Strongly Overvalued above 18.75. The current Forward EV/EBITDA of 52.81 falls within the Strongly Overvalued range.
-17.33
EV/EBIT
Castle Biosciences Inc. (CSTL) has a current EV/EBIT of -17.33. The 5-year average EV/EBIT is -15.68. The thresholds are as follows: Strongly Undervalued below -107.96, Undervalued between -107.96 and -61.82, Fairly Valued between 30.45 and -61.82, Overvalued between 30.45 and 76.59, and Strongly Overvalued above 76.59. The current Forward EV/EBIT of -17.33 falls within the Historic Trend Line -Fairly Valued range.
3.60
PS
Castle Biosciences Inc. (CSTL) has a current PS of 3.60. The 5-year average PS is 6.26. The thresholds are as follows: Strongly Undervalued below -6.14, Undervalued between -6.14 and 0.06, Fairly Valued between 12.46 and 0.06, Overvalued between 12.46 and 18.65, and Strongly Overvalued above 18.65. The current Forward PS of 3.60 falls within the Historic Trend Line -Fairly Valued range.
42.92
P/OCF
Castle Biosciences Inc. (CSTL) has a current P/OCF of 42.92. The 5-year average P/OCF is -13.04. The thresholds are as follows: Strongly Undervalued below -93.68, Undervalued between -93.68 and -53.36, Fairly Valued between 27.28 and -53.36, Overvalued between 27.28 and 67.60, and Strongly Overvalued above 67.60. The current Forward P/OCF of 42.92 falls within the Overvalued range.
55.57
P/FCF
Castle Biosciences Inc. (CSTL) has a current P/FCF of 55.57. The 5-year average P/FCF is 9.69. The thresholds are as follows: Strongly Undervalued below -202.84, Undervalued between -202.84 and -96.57, Fairly Valued between 115.96 and -96.57, Overvalued between 115.96 and 222.23, and Strongly Overvalued above 222.23. The current Forward P/FCF of 55.57 falls within the Historic Trend Line -Fairly Valued range.
Castle Biosciences Inc (CSTL) has a current Price-to-Book (P/B) ratio of 2.46. Compared to its 3-year average P/B ratio of 1.50 , the current P/B ratio is approximately 64.22% higher. Relative to its 5-year average P/B ratio of 2.15, the current P/B ratio is about 14.69% higher. Castle Biosciences Inc (CSTL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.43%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.97% , the current FCF yield is about -100.00% lower.
2.47
P/B
Median3y
1.50
Median5y
2.15
2.21
FCF Yield
Median3y
-1.43
Median5y
-1.97
Competitors Valuation Multiple
The average P/S ratio for CSTL's competitors is 0.00, providing a benchmark for relative valuation. Castle Biosciences Inc Corp (CSTL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -3.19%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CSTL increased by 48.67% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -33.24 to -91.26.
The secondary factor is the Revenue Growth, contributed -3.19%to the performance.
Overall, the performance of CSTL in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Castle Biosciences Inc (CSTL) currently overvalued or undervalued?
What is Castle Biosciences Inc (CSTL) fair value?
How does CSTL's valuation metrics compare to the industry average?
What is the current P/B ratio for Castle Biosciences Inc (CSTL) as of Dec 05 2025?
What is the current FCF Yield for Castle Biosciences Inc (CSTL) as of Dec 05 2025?
What is the current Forward P/E ratio for Castle Biosciences Inc (CSTL) as of Dec 05 2025?